Who was studied?
51 patients enrolled; 42 underwent tumor assessment by October 31, 2022.
What does the publication report?
ORR 21.4%, DCR 61.9%; median PFS 5.8 months and OS 13.5 months.
Safety findings
Four grade ≥3 treatment-related events; three patients discontinued all study treatment.
How should we interpret it?
Uncontrolled interim conference evidence, linked to NCT04892498 rather than counted as a separate trial. The abstract’s total adverse-event count and percentage are inconsistent; that percentage is not reproduced.
Read the original source
This independently written summary was checked against the publicly available abstract. Selected figures, where included, are checked against the full publication. This is not a full-paper translation or a clinical recommendation.
PD-1 inhibitors combined with radiotherapy and GM-CSF, sequentially followed by IL-2 (PRaG 2.0) regimen in advanced refractory solid tumors: A prospective, multicenter, single-arm clinical trial. · DOI: 10.1200/JCO.2023.41.16_suppl.2603
Related publications from the same research program
- PD-1 inhibitors combined with radiotherapy and GM-CSF, sequentially followed by IL-2 regimen in advanced refractory solid tumors: a prospective, multicenter clinical trial.
- PRaG 2.0: the 2023 ASTRO conference report
- A prospective, multicenter, single-arm clinical trial of PD-1 inhibitors in combination with radiotherapy and GM-CSF, sequentially followed by IL-2 (PRaG 2.0) therapy in advanced refractory solid tumors.
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.